JPS61224984A - Multiplying agent for bacterium belonging to genus bifidobacterium - Google Patents
Multiplying agent for bacterium belonging to genus bifidobacteriumInfo
- Publication number
- JPS61224984A JPS61224984A JP60067242A JP6724285A JPS61224984A JP S61224984 A JPS61224984 A JP S61224984A JP 60067242 A JP60067242 A JP 60067242A JP 6724285 A JP6724285 A JP 6724285A JP S61224984 A JPS61224984 A JP S61224984A
- Authority
- JP
- Japan
- Prior art keywords
- genus bifidobacterium
- bacterium belonging
- multiplying agent
- bacterium
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【発明の詳細な説明】
本発明はビフィドバクテリウム属細菌の増殖層をこ関す
る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a growth layer of Bifidobacterium bacteria.
ビフィドバクテリウム属のうち、ビフィズス菌は母乳栄
養児の腸内でほとんど純粋培養の状態で存在する細菌と
してよく知られていたが、ビフィズス菌が今日のように
ヒトの健康tこ、とって重要性が唱えられ、脚光を浴ひ
るに至った理由は、この菌が成人の腸内でも健康なとき
は優勢路の1つとして存在していることが確認され、ス
トレス、抗生物質投与、疾病、老化などの場合、減少し
たり、消失したりすることが明らかそこで、最近では、
この菌を利用した医薬品、食料品が多く市販されるよう
になり、医薬品では、生菌製剤が下痢、腸炎の予防、治
療に使用され、薬物での治療が不可能とされている乳児
の難治性下$jなどにも有効とされ、更に抗ガン作用と
の関係も研究されている。Bifidobacterium, a member of the genus Bifidobacterium, was well known as a bacterium that exists in almost pure culture in the intestines of breast-fed infants, but today Bifidobacterium plays an important role in human health. The reason why this bacterium has been in the spotlight is because it has been confirmed that this bacterium is present as one of the dominant routes in the intestines of adults when they are healthy. , it is clear that it decreases or disappears in cases such as aging, so recently,
Many medicines and food products using this bacterium are now on the market, and live bacteria preparations are used to prevent and treat diarrhea and enteritis, which are difficult to treat in infants that are considered impossible to treat with drugs. It is also said to be effective for sexual hypoxia, and its relationship with anti-cancer effects is also being studied.
このような事情に鑑み、ビフィズス菌を増殖する研究が
盛んとなり、古くはラクチュロース、フライノース、近
年ではフラクトオリゴ糖を使用する方法も提案されてい
る。 しかしながらこれら増殖剤は高価であり、また増
殖効果にも問題がある。In view of these circumstances, research on propagating bifidobacteria has become active, and methods using lactulose and flynose have been proposed in the past, and in recent years, methods using fructooligosaccharides have also been proposed. However, these propagation agents are expensive and have problems in their proliferative effectiveness.
そこで本発明者らはビフィドバクテリウム属細菌の増殖
剤について種々検討を重ねた結果、合成法により得られ
る安価な既知物に優れた増殖効果のあることを発見し、
かかる知見に基づき本発明を完成したものである。Therefore, the present inventors conducted various studies on growth agents for Bifidobacterium bacteria, and discovered that an inexpensive known product obtained by a synthetic method has an excellent growth effect.
The present invention was completed based on this knowledge.
既ち、本発明は、 (但し、Rは−CH,−、−CH* −OH,+。Already, the present invention has the following features: (However, R is -CH, -, -CH* -OH, +.
または−CH−CH−を示し、n−3 〜5である)で示されるN−7シルラ クタム類比合物からなるビフィドバク テリウム属#l+1の増殖剤に関する。or -CH-CH-, n-3 ~5) Bifidobacterium, which consists of Cuctum compounds Concerning a propagating agent for Therium genus #l+1.
本発明増殖剤は周知の方法 (11ラクタムと酸無水物
の反応 (2)ラクタムと酸クロリドの直接反応 (3
)5mアミン類あるいはジメチルホルムアミド存在下で
のラクタムと酸塩化物との反応(4)ラクタムのアルカ
リ金属塩と酸塩化物の反応(5)ラフチムニ−チルと酸
塩化物の反応 (6〕トリメチμシリ〜化フクタムを経
由した酸クロリドとのff応(7)2−クロロピリジニ
ウム塩による酸との中間体とラクタムとの反応などによ
り、容易に製造することができる。The propagation agent of the present invention can be produced using well-known methods (11 Reaction of lactam and acid anhydride (2) Direct reaction of lactam and acid chloride (3)
) Reaction of lactam and acid chloride in the presence of 5m amines or dimethylformamide (4) Reaction of alkali metal salt of lactam and acid chloride (5) Reaction of lafuchim nityl and acid chloride (6) Trimethyl μ It can be easily produced by ff reaction with an acid chloride via a silicate fuctam (7) Reaction of an intermediate with an acid using a 2-chloropyridinium salt and a lactam.
例えは、ラクタムと酸クロリドの直接反応法で製造する
にはフェニル酢酸、フエ二ルグロピオン酸、桂皮酸を塩
化チオニル、五塩化リン。For example, to produce lactam and acid chloride by direct reaction method, phenylacetic acid, phenylgropionic acid, and cinnamic acid are produced by thionyl chloride and phosphorus pentachloride.
三塩化リン9.塩化オキサリル等で、酸クロリド化した
後、2−ピロリドン、2−ピペリドン。Phosphorus trichloride9. After acid chloridation with oxalyl chloride etc., 2-pyrrolidone and 2-piperidone.
E−カグロラクタムと反応させることによりそれぞれ前
記一般式中に於けるRが−OH,−、−CH−CH+、
−OH,−CH,−のN−アシルラクタム類化合物を容
易に製造することができる。By reacting with E-caglolactam, R in the above general formula can be changed to -OH, -, -CH-CH+,
N-acyllactam compounds of -OH, -CH, - can be easily produced.
本発明増殖剤の使用に際しては、例えばその使用目的に
応ビてi状、粉末状1等任意形態で使用することができ
、また飲食品類tこ希望する量を添加することができる
。 さらにまた、ビフィズス菌を含有する錠菓、醗酵孔
、散剤、錠剤等tこ添加して使用してもよい。When using the proliferating agent of the present invention, it can be used in any desired form, such as a solid form or a powder form, depending on the purpose of use, and a desired amount can be added to foods and drinks. Furthermore, tablets, fermentation tubes, powders, tablets, etc. containing bifidobacteria may be added and used.
以下に本発明の実施例を掲げさらtこ説明する。Examples of the present invention will be further explained below.
製造例
5−フェニルプロピオン酸1gに塩化チオニtvsyを
加え5時間80℃に保持し、減圧下で発生ガス及び残存
塩化チオニルを除去する。Production Example 5 - Add thionyl chloride tvsy to 1 g of phenylpropionic acid, hold at 80°C for 5 hours, and remove generated gas and residual thionyl chloride under reduced pressure.
この反応物に、5−の無水ピリジンIC2−ピペリドン
0.7yを溶解した液を添加し、5時間80〜90℃に
保持し、反応混合物にエーテルを加えて、有機溶媒層を
分取し、これをIN塩酸溶液、1N水酸化す) IJウ
ム溶液、水で順次洗浄し、芒硝で脱水後溶媒を留去する
。 残渣を酢酸エチ〜、n−ヘキサンの混合溶媒に溶解
後結晶化ヲ行ない、+−(5−フェニルプロパノイN)
−2−ヒ1ペリトンL86Fを得た。To this reaction mixture, a solution containing 0.7y of 5-anhydrous pyridine IC2-piperidone was added and maintained at 80 to 90°C for 5 hours, ether was added to the reaction mixture, and the organic solvent layer was separated. This was washed successively with an IN hydrochloric acid solution, an IJ solution, and water, and after dehydration with sodium sulfate, the solvent was distilled off. The residue was dissolved in a mixed solvent of ethyl acetate and n-hexane and crystallized to give +-(5-phenylpropanoyl N).
-2-Hyperitone L86F was obtained.
実施例1
第1表に示す増殖剤をBL寒天培地にツスイ製)+1!
1こ対し、10岬添加した試験培地を使用し、嫌気条件
下35℃48時間各種ビフィドバクテリウム属細菌の増
殖に対する影響を測定した。 使用した菌株を第2表に
その結果な第6表に示す。Example 1 The growth agents shown in Table 1 were added to a BL agar medium (Tsui) +1!
Using a test medium to which 10 capes were added per sample, the influence on the growth of various Bifidobacterium bacteria was measured under anaerobic conditions at 35°C for 48 hours. The strains used are shown in Table 2, and the results are shown in Table 6.
第1表 供試試料
第2表
第3表
実施例2
成人男子糞便(55歳)を検体とし、実施例と同法によ
り、糞便中のフローラに対する1−(2−7エニルエタ
ノイIv) −2−?”ペリトン、5μ2β (培地容
量)の影響を全菌数及びフローラの相異を測定した。
全菌数及びビフィドバクテリウム属細菌数を第4表に示
す。Table 1 Test Samples Table 2 Table 3 Example 2 Adult male feces (55 years old) was used as a sample, and 1-(2-7 enyl ethanoyl Iv) -2- ? The effects of Peritone and 5μ2β (medium volume) were measured on the total number of bacteria and differences in flora.
Table 4 shows the total number of bacteria and the number of Bifidobacterium bacteria.
第4表
実施例3
実施例2と同じ試験を1−(3−フエニρプロバノイ/
I/)−2−ピロリドンを使用し、新生児糞便を検体と
して行なった。 ビフィドバクテリウム属細菌の全菌
数を第5表に示す。Table 4 Example 3 The same test as Example 2 was carried out using
I/)-2-pyrrolidone was used and newborn feces were used as the specimen. Table 5 shows the total number of Bifidobacterium bacteria.
第5表Table 5
Claims (1)
または−CH=CH−を示し、n=3〜 5である)で示されるN−アシルラク タム類化合物からなるビフィドバクテ リウム属細菌の増殖剤。[Claims] General formula ▲ Numerical formula, chemical formula, table, etc. ▼ (However, R is -CH_2-, -CH_3-CH_2-,
or -CH═CH-, and n=3 to 5), a growth agent for Bifidobacterium bacteria.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60067242A JPS61224984A (en) | 1985-03-30 | 1985-03-30 | Multiplying agent for bacterium belonging to genus bifidobacterium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60067242A JPS61224984A (en) | 1985-03-30 | 1985-03-30 | Multiplying agent for bacterium belonging to genus bifidobacterium |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61224984A true JPS61224984A (en) | 1986-10-06 |
JPH0468910B2 JPH0468910B2 (en) | 1992-11-04 |
Family
ID=13339251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60067242A Granted JPS61224984A (en) | 1985-03-30 | 1985-03-30 | Multiplying agent for bacterium belonging to genus bifidobacterium |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61224984A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0943609A1 (en) * | 1998-03-18 | 1999-09-22 | Toa Pharmaceutical Co., Ltd. | Azetidine derivative, bifidobacterium division-promoting composition containing the same, and a process for production thereof |
JPWO2020175690A1 (en) * | 2019-02-28 | 2020-09-03 |
-
1985
- 1985-03-30 JP JP60067242A patent/JPS61224984A/en active Granted
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0943609A1 (en) * | 1998-03-18 | 1999-09-22 | Toa Pharmaceutical Co., Ltd. | Azetidine derivative, bifidobacterium division-promoting composition containing the same, and a process for production thereof |
JPWO2020175690A1 (en) * | 2019-02-28 | 2020-09-03 |
Also Published As
Publication number | Publication date |
---|---|
JPH0468910B2 (en) | 1992-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hollifield Jr et al. | Ferric enterobactin transport system in Escherichia coli K-12. Extraction, assay, and specificity of the outer membrane receptor | |
Yamamoto et al. | Isolation and structure elucidation of acinetobactin., a novel siderophore from Acinetobacter baumannii | |
Rotstein et al. | Succinic acid, a metabolic by-product of Bacteroides species, inhibits polymorphonuclear leukocyte function | |
Fujioka et al. | Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids | |
Goetzl et al. | Modulation of human neutrophil function by monohydroxy-eicosatetraenoic acids. | |
Toeplitz et al. | Structure of ionomycin-a novel diacidic polyether antibiotic having high affinity for calcium ions | |
Loos et al. | Interaction of purified lipoteichoic acid with the classical complement pathway | |
Braun et al. | The biosynthesis of dihydrosphingosine in cell-free preparations of Hansenula ciferri. | |
WO1988008452A1 (en) | Antibiotic reuterin | |
FR2395990A1 (en) | A-ACETYLENIC DERIVATIVES OF AMINES USEFUL IN PARTICULAR AS INHIBITORS OF CERTAIN DECARBOXYLASES AND THEIR PROCESS FOR PREPARATION | |
US5352586A (en) | Method of determining the presence of an antibiotic produced by Lactobacillus reuteri | |
Anding et al. | Nonspecific biosynthesis of hopane triterpenes in a cell-free system from Acetobacter rancens | |
JPS61224984A (en) | Multiplying agent for bacterium belonging to genus bifidobacterium | |
GB1528763A (en) | Carbocyclic-fused pyridine derivatives | |
Noble et al. | Incorporation of propionic acid into a branched-chain fatty acid of the preen gland of the goose | |
Caillon et al. | Occurrence of dialkyl ether phospholipids in Stigmatella aurantiaca DW4 | |
WO1993002185A1 (en) | Acat inhibitor | |
JP3315826B2 (en) | Bifidobacterium growth promotion composition | |
Badgett et al. | Nicotinic acid. Water-insoluble esters and amides | |
Jenkin et al. | Effect of isomeric cis-octadecenoic acids on the growth of Leptospira interrogans serotype patoc | |
McCormick et al. | On the nature of the reversible isomerizations occurring in the tetracycline family | |
GB1565083A (en) | Pseudomonic acid amides | |
Field et al. | Effects of fatty acids on growth of Bordetella pertussis in defined medium | |
US5929109A (en) | Enhancing and stabilizing agent of the activity of Bifidus factor | |
Cook et al. | Antibiotics produced by fungi, and a new phenomenon in optical resolution |